RABİA NAZİK EKİNCİ, ŞEYMA UYGUN
Psychiatry and Behavioral Sciences - 2025;15(1):25-35
Objective: Lurasidone is among the new treatment options that have recently become available in our country.. In this review, it is aimed to contribute to the clinical use of antipsychotics by evaluating the mechanism of action and indications for lurasidone. Method: An extensive literature search on lurasidone was conducted for this review. Results: Lurasidone, a benzisothiazole group atypical antipsychotic, is metabolized in the liver by the CYP3A4 enzyme system. Like other atypical antipsychotics, it has multimodal activity. While it affects positive symptoms with its antagonistic effect on dopamine D2 receptors and serotonin 5-HT2A receptors, it has a positive effect on cognition with 5-HT7 antagonism and 5-HT1A partial agonism and provides improvement in depressive symptoms. It has no affinity for H1 and M1 receptors and seems to be at lower risk for side effects such as weight gain and sedation compared to other atypical antipsychotics. It has been found effective in the treatment of schizophrenia and bipolar disorder depressive episodes. Conclusion: Lurasidone has advantages over many antipsychotics in terms of side effects such as weight gain, metabolic effects, sedation, cognitive impairment, Qt interval prolongation and seems to be an important alternative among the new generation antipsychotics with its effect on both positive and negative symptoms of schizophrenia and its effect on the depressive episode of bipolar disorder.
